NCT01544894

Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis

Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: University of Valencia · Academic / Other
• Sex: Female
• Age: 50 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.

Detailed description

OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis. DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year. MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers.

Conditions

• Postmenopausal Osteoporosis
• Compliance

Interventions

Type	Name	Description
DRUG	Raloxifene	60 mg/d for one year
DRUG	Strontium ranelate	2 g/d, for one year

Timeline

• Start date: 2009-09-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2012-03-06
• Last updated: 2012-09-03

Locations

1 site across 1 country: Spain